DK1420827T3 - 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter - Google Patents

5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter

Info

Publication number: DK1420827T3
Authority: DK; Denmark
Prior art keywords: parathyroid hormone; cnac; oral administration; administration agent; hormone fragments
Prior art date: 2001-08-17

Application number

DK02794796T

Other languages

English (en)

Inventor

Simon David Bateman

Moise Azria

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-17

Filing date

2002-08-16

Publication date

2009-12-21

2002-08-16 Application filed by Novartis Ag filed Critical Novartis Ag

2009-12-21 Application granted granted Critical

2009-12-21 Publication of DK1420827T3 publication Critical patent/DK1420827T3/da

Links

108090000445 Parathyroid hormone Proteins 0.000 title abstract 3
239000000199 parathyroid hormone Substances 0.000 title abstract 2
229960001319 parathyroid hormone Drugs 0.000 title abstract 2
XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 title 1
102000003982 Parathyroid hormone Human genes 0.000 title 1
239000003795 chemical substances by application Substances 0.000 title 1
239000012634 fragment Substances 0.000 title 1
102100036893 Parathyroid hormone Human genes 0.000 abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000011164 ossification Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK02794796T 2001-08-17 2002-08-16 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter DK1420827T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31304801P	2001-08-17	2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en)	2001-08-17	2002-08-16	5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number	Publication Date
DK1420827T3 true DK1420827T3 (da)	2009-12-21

Family

ID=23214149

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02794796T DK1420827T3 (da)	2001-08-17	2002-08-16	5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter

Country Status (26)

Country	Link
US (4)	US20040242478A1 (da)
EP (1)	EP1420827B8 (da)
JP (2)	JP4959917B2 (da)
KR (1)	KR20040030120A (da)
CN (1)	CN1279981C (da)
AT (1)	ATE443527T1 (da)
AU (1)	AU2002333443C1 (da)
BR (1)	BRPI0211932B1 (da)
CA (1)	CA2453646C (da)
CO (1)	CO5560586A2 (da)
CY (1)	CY1109661T1 (da)
DE (1)	DE60233803D1 (da)
DK (1)	DK1420827T3 (da)
EC (1)	ECSP044961A (da)
ES (1)	ES2333587T3 (da)
HU (1)	HUP0401441A3 (da)
IL (2)	IL159714A0 (da)
MX (1)	MXPA04001418A (da)
NO (1)	NO328069B1 (da)
NZ (1)	NZ531018A (da)
PL (1)	PL210258B1 (da)
PT (1)	PT1420827E (da)
RU (1)	RU2322256C2 (da)
SI (1)	SI1420827T1 (da)
WO (1)	WO2003015822A1 (da)
ZA (1)	ZA200400242B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5073153B2 (ja) *	2001-06-01	2012-11-14	ノバルティスアーゲー	副甲状腺ホルモンおよびカルシトニンの経口投与
DE60233803D1 (de) *	2001-08-17	2009-11-05	Novartis Ag	5-cnac zur oralen verabreichung von parathormonfragmenten
WO2003086408A1 (en) *	2002-04-10	2003-10-23	University Of Virginia Patent Foundation	Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
PT2316473E (pt)	2003-07-23	2013-09-20	Novartis Ag	Utilização de calcitonina na osteoartrite
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
US8110547B2 (en) *	2005-01-12	2012-02-07	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
EP1896134A2 (en) *	2005-06-13	2008-03-12	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders
PE20070548A1 (es)	2005-09-19	2007-07-12	Emisphere Tech Inc	Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
WO2007059470A2 (en) *	2005-11-10	2007-05-24	Board Of Control Of Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2059260B1 (en) *	2006-08-31	2013-06-19	Novartis AG	Pharmaceutical compositions comprising hGH for oral delivery
WO2008109385A2 (en)	2007-03-02	2008-09-12	Novartis Ag	Oral administration of a calcitonin
US8022048B2 (en)	2007-11-02	2011-09-20	Emisphere Technologies, Inc.	Method of treating vitamin B12 deficiency
WO2011071480A1 (en)	2009-12-07	2011-06-16	Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en)	2011-03-31	2012-10-04	Zentiva, K.S.	Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
WO2016128972A1 (en)	2015-02-09	2016-08-18	Entera Bio Ltd.	Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es)	2016-08-17	2019-05-15	Entera Bio Ltd	Formulaciones para administracion oral de principios activos.
KR101796604B1 (ko) *	2016-08-30	2017-11-10	목포대학교 산학협력단	위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4692433A (en) *	1983-10-12	1987-09-08	The Regents Of The University Of California	Method and composition for regulating serum calcium levels of mammals
HUT68010A (en) *	1991-12-17	1995-05-29	Procter & Gamble Pharma	The use of bisphonates and parathyroid hormone for the treatment of osteoporosis
DK0679088T3 (da) *	1992-09-29	2002-10-28	Inhale Therapeutic Syst	Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
PT915911E (pt) *	1996-08-02	2004-03-31	Ca Nat Research Council	Analogos da hormona paratiroideia para o tratamento de osteoporose
ATE383169T1 (de) *	1997-02-07	2008-01-15	Emisphere Tech Inc	Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) *	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
WO2000031137A1 (en) *	1998-11-25	2000-06-02	The General Hospital Corporation	Amino-terminal modified parathyroid hormone (pth) analogs
NZ534409A (en) *	1999-04-05	2006-03-31	Emisphere Tech Inc	Disodium salts, monohydrates, and ethanol solvates for delivering active agents
JP4799794B2 (ja) *	2000-03-21	2011-10-26	エミスフェアー・テクノロジーズ・インク	ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
JP5073153B2 (ja) *	2001-06-01	2012-11-14	ノバルティスアーゲー	副甲状腺ホルモンおよびカルシトニンの経口投与
DE60233803D1 (de) *	2001-08-17	2009-11-05	Novartis Ag	5-cnac zur oralen verabreichung von parathormonfragmenten
MXPA06000446A (es) *	2003-07-11	2006-04-07	Novartis Ag	Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.

2002
- 2002-08-16 DE DE60233803T patent/DE60233803D1/de not_active Expired - Lifetime
- 2002-08-16 MX MXPA04001418A patent/MXPA04001418A/es active IP Right Grant
- 2002-08-16 KR KR10-2004-7002277A patent/KR20040030120A/ko not_active Ceased
- 2002-08-16 JP JP2003520780A patent/JP4959917B2/ja not_active Expired - Fee Related
- 2002-08-16 SI SI200230866T patent/SI1420827T1/sl unknown
- 2002-08-16 NZ NZ531018A patent/NZ531018A/xx not_active IP Right Cessation
- 2002-08-16 PL PL365388A patent/PL210258B1/pl unknown
- 2002-08-16 RU RU2004107899/15A patent/RU2322256C2/ru not_active IP Right Cessation
- 2002-08-16 AT AT02794796T patent/ATE443527T1/de active
- 2002-08-16 US US10/484,331 patent/US20040242478A1/en not_active Abandoned
- 2002-08-16 EP EP02794796A patent/EP1420827B8/en not_active Expired - Lifetime
- 2002-08-16 DK DK02794796T patent/DK1420827T3/da active
- 2002-08-16 CN CNB028160843A patent/CN1279981C/zh not_active Expired - Fee Related
- 2002-08-16 ES ES02794796T patent/ES2333587T3/es not_active Expired - Lifetime
- 2002-08-16 WO PCT/EP2002/009181 patent/WO2003015822A1/en not_active Ceased
- 2002-08-16 BR BRPI0211932A patent/BRPI0211932B1/pt not_active IP Right Cessation
- 2002-08-16 IL IL15971402A patent/IL159714A0/xx unknown
- 2002-08-16 HU HU0401441A patent/HUP0401441A3/hu unknown
- 2002-08-16 AU AU2002333443A patent/AU2002333443C1/en not_active Ceased
- 2002-08-16 PT PT02794796T patent/PT1420827E/pt unknown
- 2002-08-16 CA CA002453646A patent/CA2453646C/en not_active Expired - Lifetime
2004
- 2004-01-05 IL IL159714A patent/IL159714A/en not_active IP Right Cessation
- 2004-01-13 ZA ZA200400242A patent/ZA200400242B/en unknown
- 2004-01-29 EC EC2004004961A patent/ECSP044961A/es unknown
- 2004-02-10 NO NO20040598A patent/NO328069B1/no not_active IP Right Cessation
- 2004-02-17 CO CO04013136A patent/CO5560586A2/es not_active Application Discontinuation
2006
- 2006-05-30 US US11/443,528 patent/US20060217313A1/en not_active Abandoned
2009
- 2009-06-09 JP JP2009138067A patent/JP2009242410A/ja not_active Withdrawn
- 2009-07-01 US US12/495,966 patent/US20090264367A1/en not_active Abandoned
- 2009-11-25 CY CY20091101231T patent/CY1109661T1/el unknown
2011
- 2011-12-15 US US13/327,114 patent/US9272040B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1279981C (zh)	2006-10-18
US20060217313A1 (en)	2006-09-28
ZA200400242B (en)	2004-11-18
PL210258B1 (pl)	2011-12-30
BRPI0211932B1 (pt)	2016-12-06
CO5560586A2 (es)	2005-09-30
PL365388A1 (en)	2005-01-10
PT1420827E (pt)	2009-12-15
JP2009242410A (ja)	2009-10-22
JP4959917B2 (ja)	2012-06-27
EP1420827A1 (en)	2004-05-26
ECSP044961A (es)	2004-03-23
NO328069B1 (no)	2009-11-23
US9272040B2 (en)	2016-03-01
US20120088725A1 (en)	2012-04-12
JP2005501852A (ja)	2005-01-20
HUP0401441A2 (hu)	2004-12-28
MXPA04001418A (es)	2004-05-27
CY1109661T1 (el)	2014-08-13
CA2453646A1 (en)	2003-02-27
NO20040598L (no)	2004-02-10
IL159714A (en)	2010-12-30
WO2003015822A1 (en)	2003-02-27
CA2453646C (en)	2008-09-30
ATE443527T1 (de)	2009-10-15
US20090264367A1 (en)	2009-10-22
RU2322256C2 (ru)	2008-04-20
HUP0401441A3 (en)	2012-09-28
CN1543357A (zh)	2004-11-03
EP1420827B1 (en)	2009-09-23
AU2002333443C1 (en)	2009-10-08
NZ531018A (en)	2006-03-31
SI1420827T1 (sl)	2010-01-29
EP1420827B8 (en)	2009-12-23
US20040242478A1 (en)	2004-12-02
AU2002333443B2 (en)	2006-06-29
KR20040030120A (ko)	2004-04-08
DE60233803D1 (de)	2009-11-05
BR0211932A (pt)	2004-10-26
IL159714A0 (en)	2004-06-20
ES2333587T3 (es)	2010-02-24
RU2004107899A (ru)	2005-05-10

Publication	Publication Date	Title
NO20040598L (no)	2004-02-10	5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
MXPA03007837A (es)	2004-03-16	Composiciones para suministrar bisfosfonatos.
IL175158A0 (en)	2006-09-05	Tocopherol-modified therapeutic drug compounds
MXPA04008068A (es)	2004-11-26	Metodo para administrar moleculas de glp-1.
MXPA06012980A (es)	2007-06-12	Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
AU2003301190A8 (en)	2004-07-14	Administration of capsaicinoids
IL220043A0 (en)	2012-06-28	Methods for producing ??-galactosidase a compositions
ATE500218T1 (de)	2011-03-15	Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
GT199700009AA (es)	1999-01-23	Terapia combinada para la osteoporosis
LU91281I2 (fr)	2006-12-19	Preotact-hormone parathyroïde
ATE356631T1 (de)	2007-04-15	Orale verabreichung von parathyroidhormon und calcitonin
WO2004073615A3 (en)	2005-06-16	Deazaflavin compounds and methods of use thereof
TW200511999A (en)	2005-04-01	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL368686A1 (en)	2005-04-04	Novel aminobenzoephenones
PL370361A1 (en)	2005-05-16	Alkyl urea retinoid agonists i
NO20054034L (no)	2005-10-05	Fremgangsmate for behandling av hypotyroidisme.
UA66932C2 (en)	2004-06-15	Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
AU2003286617A8 (en)	2004-06-03	Calcitonin drug-oligomer conjugates, and uses thereof
PL370459A1 (en)	2005-05-30	Substituted urea retinoid agonists ii
AU2002319223A1 (en)	2002-12-23	Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
TW200509960A (en)	2005-03-16	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
MXPA05003633A (es)	2005-12-14	2"-oxo-voruscharina y derivados de la misma.
TW200519078A (en)	2005-06-16	2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
IL125983A0 (en)	1999-04-11	Pharmaceutical composition comprising factor xiiia